January 13, 2022
Administered as an injection every other month, Apretude gives people at risk of contracting HIV a PrEP alternative to taking daily pills.
December 27, 2021
Apretude is approved for use in at-risk adults and adolescent to reduce the risk of sexually acquired HIV.
July 13, 2020
The data from a new study has shown that investigational, long-acting injectable cabotegravir boasted a 66% higher efficacy than daily oral pills in preventing HIV-1.
July 09, 2020
Both trial sub-analyses will be presented at the virtual 23rd International AIDS Conference.
July 08, 2020
Survey results on PrEP access and utilization during COVID-19 shelter-in-place orders presented at the 23rd International AIDS Conference.
July 03, 2020
Fostemsavir (Rukobia, ViiV Healthcare) is indicated for use in heavily treatment-experienced adults with multidrug resistant HIV-1 infection.
June 12, 2020
Officials with the FDA have approved dolutegravir (Tivicay PD, ViiV Healthcare) dispersible tablets for oral suspension for children who are at least 4 weeks of age and weigh at least 3 kg.
June 08, 2020
Virtual care takes center stage amid the pandemic.
May 20, 2020
A new review in JAMA Pediatrics looks at the current status of PrEP uptake among adolescents aged 13 to 19 years who are at risk for HIV.
April 30, 2020
In-depth interviews from 59 women living with HIV revealed that many women preferred long-acting injectable antiretroviral therapy for its convenience, privacy, and perceived effectiveness.
